Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OTC | P00480 | 1/20 | 0.58 |
| ▸ | GSR | P00390 | 1/20 | 0.57 |
| ▸ | ARG2 | P78540 | 4/20 | 0.47 |
| ▸ | ARG1 | P05089 | 3/20 | 0.47 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.46 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.45 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.45 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.45 |
| ▸ | DDAH1 | O94760 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.43 |
| ▸ | NOS3 | P29474 | 2/20 | 0.42 |
| ▸ | NOS1 | P29475 | 2/20 | 0.42 |
| ▸ | NOS2 | P35228 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL358166 | 1.00 | OTC (0.58) | OTCGSRARG2ARG1NOD1 | |
| SCHEMBL3460656 | 1.00 | OTC (0.58) | OTCGSRARG2ARG1NOD1 | |
| SCHEMBL13043221 | 0.94 | OTC (0.65) | OTCGSRARG2ARG1NOD1 | |
| SCHEMBL21611913 | 0.93 | OTC (0.53) | OTCGSRARG2ARG1NOD1 | |
| SCHEMBL1768369 | 0.86 | OTC (0.50) | OTCGSRNOD1CYP1A2 | |
| SCHEMBL1768374 | 0.86 | OTC (0.50) | OTCGSRNOD1CYP1A2 | |
| SCHEMBL27841191 | 0.86 | OTC (0.55) | OTCGSRARG2ARG1NOD1 | |
| SCHEMBL12238274 | 0.86 | OTC (0.55) | OTCGSRARG2ARG1NOD1 | |
| SCHEMBL18924743 | 0.86 | GSR (0.58) | OTCGSRARG2ARG1NOD1 | |
| SCHEMBL5974000 | 0.85 | OTC (0.58) | OTCGSRARG2ARG1NOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023176966-A1 | CROSSLINKED PRODUCT OF MODIFIED POLYASPARTIC ACID OR SALT THEREOF, AND THICKENING COMPOSITION | DIC株式会社 | 2023-09-21 | — | — | WO | disclosed |
| WO-2023155060-A1 | CROSS-LINKED POLY (ASPARTIC ACID ) PRODUCT AND METHOD FOR PRODUCING THE SAME | DIC CORPORATION (JP) | 2023-08-24 | — | — | WO | disclosed |
| WO-2023155523-A1 | CROSS-LINKED POLY (ASPARTIC ACID) PRODUCT AND METHOD FOR PRODUCING SAME | DIC CORPORATION (JP) | 2023-08-24 | — | — | WO | disclosed |
| US-20230159547-A1 | COMPOUND AND LABELED BIOLOGICAL SUBSTANCE USING THE SAME | FUJIFILM CORPORATION (JP) | 2023-05-25 | — | — | US | disclosed |
| EP-2981282-B1 | GROWTH HORMONE COMPOUND FORMULATION | NOVO NORDISK HEALTHCARE AG (CH) | 2020-11-04 | — | — | EP | disclosed |
| WO-2004037159-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR MODULATING FAT METABOLISM | OBETHERAPY BIOTECHNOLOGY (FR) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159547-A1 | COMPOUND AND LABELED BIOLOGICAL SUBSTANCE USING THE SAME | CD209, MRPL9, RXFP1 | OTC 4194/4885GSR 3632/4885ARG2 495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.